ArticleFrontiers in immunology2026
LGMN promotes crosstalk between macrophages and fibroblasts in pulmonary fibrosis: a potential therapeutic target.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Macrophages play a crucial role in the progression of idiopathic pulmonary fibrosis (IPF). This study aims to identify a predictive signature based on macrophage-related genes to forecast patient prognosis and uncover potential therapeutic targets for IPF. Methods: We analyzed single-cell transcriptomic and microarray data from the GEO database, exploring cellular variations in healthy controls, COPD, and IPF patients. CellChat and Monocle were utilized for analyzing cell interactions and pseudotime trajectories, respectively. Bioinformatics was used to identify differentially expressed genes, leading to the development of a gene signature via multivariate Cox regression, which was validated using ROC curves and an external dataset. The biological function of LGMN was investigated through Results: We observed a significant increase in monocyte-derived macrophages (MDMs) in patients with IPF, which negatively correlated with lung function. In IPF patients, interactions between macrophages and fibroblasts, as well as myofibroblasts, were both more frequent and intense compared to those observed in controls. Notably, the TGF-β1 signaling pathway was significantly activated in IPF, particularly within MDMs and myofibroblasts, leading to increased extracellular matrix (ECM) activity. We developed a gene signature associated with MDMs, which serves as an independent prognostic tool for IPF patients. Conclusions: Our research establishes a gene signature associated with MDMs, which may aid clinicians in the personalized management of IPF. Additionally, we identify LGMN as a promoter of interaction between M2 macrophages and fibroblasts, suggesting its potential as a therapeutic target for IPF treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.